Luc Mouthon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5756338/publications.pdf

Version: 2024-02-01

		126907	58581
98	7,707	33	82
papers	citations	h-index	g-index
00	2.2	0.0	1.40.47
99	99	99	14947
all docs	docs citations	times ranked	citing authors

#	Article	lF	CITATIONS
1	Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science, 2020, 369, 718-724.	12.6	2,374
2	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. Cell, 2020, 182, 1401-1418.e18.	28.9	663
3	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	2.8	605
4	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.9	410
5	Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. European Journal of Internal Medicine, 2015, 26, 545-553.	2.2	371
6	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ, The, 2020, 369, m1844.	6.0	355
7	Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nature Medicine, 2022, 28, 1297-1302.	30.7	235
8	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Annals of the Rheumatic Diseases, 2018, 77, 1143-1149.	0.9	219
9	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Annals of the Rheumatic Diseases, 2018, 77, 1150-1156.	0.9	139
10	Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named) Tj ETQq0 0 0 rgBT	Overlock	10 Tf 50 382 136
11	Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: A new overlap syndrome. Autoimmunity Reviews, 2017, 16, 1036-1043.	5.8	120
12	Is Pulmonary Arterial Hypertension Really a Late Complication of Systemic Sclerosis?. Chest, 2009, 136, 1211-1219.	0.8	117
13	Adding Azathioprine to Remissionâ€Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churgâ€Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors. Arthritis and Rheumatology, 2017, 69, 2175-2186.	5.6	117
14	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Annals of Internal Medicine, 2020, 173, 179-187.	3.9	116
15	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death and Disease, 2021, 12, 258.	6.3	113
16	Central nervous system involvement of granulomatosis with polyangiitis: clinical-radiological presentation distinguishes different outcomes. Rheumatology, 2015, 54, 424-432.	1.9	89
17	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
18	Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmunity Reviews, 2005, 4, 264-269.	5.8	71

#	Article	IF	CITATIONS
19	Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. Autoimmunity Reviews, 2017, 16, 963-969.	5. 8	70
20	Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 2016, 11, 141.	2.7	62
21	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. Arthritis Care and Research, 2017, 69, 1050-1059.	3.4	52
22	Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. Autoimmunity Reviews, 2015, 14, 996-1004.	5.8	50
23	Patient preference disability questionnaire in systemic sclerosis: A crossâ€sectional survey. Arthritis and Rheumatism, 2008, 59, 968-973.	6.7	49
24	Relevance of diagnostic investigations in patients with uveitis: Retrospective cohort study on 300 patients. Autoimmunity Reviews, 2017, 16, 504-511.	5.8	46
25	Risk of scleroderma according to the type of immune checkpoint inhibitors. Autoimmunity Reviews, 2020, 19, 102596.	5.8	44
26	Ocular involvement in granulomatosis with polyangiitis: A single-center cohort study on 63 patients. Autoimmunity Reviews, 2019, 18, 493-500.	5.8	43
27	Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. Journal of Autoimmunity, 2020, 106, 102338.	6.5	43
28	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case–control study from the French Vasculitis Study Group Registry. Autoimmunity Reviews, 2018, 17, 108-114.	5.8	42
29	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
30	Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Annals of the Rheumatic Diseases, 2022, 81, 720-728.	0.9	39
31	Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. Rheumatology, 2015, 54, 1852-1857.	1.9	38
32	Impact of cardiac magnetic resonance imaging on eosinophilic granulomatosis with polyangiitis outcomes: A long-term retrospective study on 42 patients. Autoimmunity Reviews, 2015, 14, 774-780.	5.8	37
33	Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. Rheumatology, 2019, 58, 401-409.	1.9	35
34	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. Journal of Autoimmunity, 2015, 65, 49-55.	6.5	34
35	Clinical and pathological significance of cutaneous manifestations in ANCA-associated vasculitides. Autoimmunity Reviews, $2017, 16, 1138-1146$.	5.8	32
36	Deep Learning–based Approach for Automated Assessment of Interstitial Lung Disease in Systemic Sclerosis on CT Images. Radiology: Artificial Intelligence, 2020, 2, e190006.	5.8	32

#	Article	IF	CITATIONS
37	Postrehabilitation Functional Improvements in Patients With Inflammatory Myopathies: The Results of a Randomized Controlled Trial. Archives of Physical Medicine and Rehabilitation, 2017, 98, 227-234.	0.9	31
38	Elastic Registration–driven Deep Learning for Longitudinal Assessment of Systemic Sclerosis Interstitial Lung Disease at CT. Radiology, 2021, 298, 189-198.	7.3	28
39	Microscopic polyangiitis: Clinical characteristics and long-term outcomes of 378 patients from the French Vasculitis Study Group Registry. Journal of Autoimmunity, 2020, 112, 102467.	6.5	25
40	Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. Journal of Allergy and Clinical Immunology, 2022, 149, 550-556.e2.	2.9	25
41	Scleroderma Renal Crisis. Rheumatic Disease Clinics of North America, 2015, 41, 475-488.	1.9	24
42	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis. Rheumatology, 2020, 59, 3807-3816.	1.9	24
43	Pre-test probability for SARS-Cov-2-related infection score: The PARIS score. PLoS ONE, 2020, 15, e0243342.	2.5	24
44	Pneumococcal and influenza vaccination rates in patients treated with corticosteroids and/or immunosuppressive therapies for systemic autoimmune diseases: A cross-sectional study. Joint Bone Spine, 2017, 84, 365-366.	1.6	21
45	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology, 2021, 60, 4355-4360.	1.9	21
46	Low influenza vaccination rate among patients with systemic sclerosis. Rheumatology, 2010, 49, 600-606.	1.9	18
47	Management of secondary immune deficiencies. Current Opinion in Allergy and Clinical Immunology, 2013, 13, S56-S67.	2.3	18
48	Use of Elastic Registration in Pulmonary MRI for the Assessment of Pulmonary Fibrosis in Patients with Systemic Sclerosis. Radiology, 2019, 291, 487-492.	7.3	18
49	Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. JAMA Network Open, 2022, 5, e2220925.	5.9	18
50	Novelties in the field of autoimmunity $\hat{a} \in ``1st Saint Petersburg congress of autoimmunity, the bridge between east and west. Autoimmunity Reviews, 2017, 16, 1175-1184.$	5.8	17
51	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study. Seminars in Arthritis and Rheumatism, 2014, 43, 681-688.	3.4	15
52	Systemic sclerosis: Sexual dysfunction and lower urinary tract symptoms in 73 patients. Presse Medicale, 2016, 45, e79-e89.	1.9	15
53	Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. Autoimmunity Reviews, 2018, 17, 984-989.	5.8	15
54	Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2016, 1, 234-240.	1.7	14

#	Article	IF	Citations
55	Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU®) patient-reported outcome instrument. Arthritis Research and Therapy, 2020, 22, 3.	3.5	13
56	A role for IL-33–activated ILC2s in eosinophilic vasculitis. JCI Insight, 2021, 6, .	5.0	12
57	Serum 1,25(OH) ₂ Vitamin D and 25(OH) Vitamin D Ratio for the Diagnosis of Sarcoidosis-Related Uveitis. Ocular Immunology and Inflammation, 2020, 28, 341-347.	1.8	11
58	Myeloproliferative neoplasms and clonal haematopoiesis in patients with giant cell arteritis: a caseâ€"control and exploratory study. Rheumatology, 2022, 61, 775-780.	1.9	11
59	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody–associated Vasculitis-related Bronchiectasis: Data from 61 Patients. Journal of Rheumatology, 2020, 47, 1522-1531.	2.0	10
60	Persistent Nasal Inflammation 5 Months after Acute Anosmia in Patients with COVID-19. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1319-1322.	5.6	10
61	Presentation, Diagnosis, and Management of Subglottic and Tracheal Stenosis During Systemic Inflammatory Diseases. Chest, 2022, 161, 257-265.	0.8	10
62	A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. Clinical and Experimental Rheumatology, 2021, 39, 155-160.	0.8	10
63	Clinical characteristics and persistence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in 4,607 French healthcare workers: Comparison with European countries. Infection Control and Hospital Epidemiology, 2020, 42, 1-2.	1.8	9
64	An immunohistochemical analysis of fibroblasts in giant cell arteritis. Annals of Diagnostic Pathology, 2021, 52, 151728.	1.3	9
65	Employment, work disability and quality of life in patients with ANCA-associated vasculitides. The EXPOVAS study. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 40-46.	0.8	9
66	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. RMD Open, 2022, 8, e002160.	3.8	9
67	Controlling the digital ulcerative disease in systemic sclerosis is associated with improved hand function. Seminars in Arthritis and Rheumatism, 2017, 46, 759-766.	3.4	8
68	Patients of 75 years and over with ANCAâ€associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. Journal of Internal Medicine, 2021, , .	6.0	8
69	Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary SjÁ¶gren's syndrome patients. Rheumatology, 2022, 61, 3818-3823.	1.9	8
70	Risk of malignancy in patients treated for systemic necrotising vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 431-433.	0.9	7
71	Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 176-184.	0.8	7
72	Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis. Diagnostics, 2021, 11, 1064.	2.6	6

#	Article	IF	CITATIONS
73	Atypical Vasculitis Mimicking Chronic Thromboembolic Pulmonary Hypertension. American Journal of Medicine, 2015, 128, e47-e49.	1.5	5
74	Costs of Intravenous Immunoglobulin Therapy in Patients With Unconfirmed Parvovirus B19 Pure Red Cell Aplasia. Clinical Infectious Diseases, 2015, 60, 488-488.	5.8	5
75	Rituximab plus methotrexate combination as a salvage therapy in persistently active granulomatosis with polyangiitis. Rheumatology, 2022, 61, 2619-2624.	1.9	5
76	Chronic obstructive pulmonary disease associated with hypocomplementemic urticarial vasculitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3222-3224.e1.	3.8	4
77	Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis. Ocular Immunology and Inflammation, 2021, 29, 290-298.	1.8	4
78	Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients. Arthritis Research and Therapy, 2021, 23, 134.	3.5	4
79	Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French population. Rheumatology, 2016, 56, kew423.	1.9	3
80	Free prednisolone pharmacokinetics predicted from total concentrations in patients with inflammatory – immunonologic conditions. Fundamental and Clinical Pharmacology, 2020, 34, 270-278.	1.9	3
81	IgA monoclonal gammopathy associated with refractory IgA vasculitis successfully treated with clone-targeted therapy. Autoimmunity Reviews, 2020, 19, 102611.	5.8	3
82	A French cohort of patients with giant cell arteritis: glucocorticoid treatment and its associated side effects. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 155-160.	0.8	3
83	Health Outcomes of 215 Mothers of Children With Autoimmune Congenital Heart Block: Analysis of the French Neonatal Lupus Syndrome Registry. Journal of Rheumatology, 2022, 49, 1124-1130.	2.0	3
84	Systemic sclerosis: Views and thoughts for the future. Presse Medicale, 2014, 43, e265-e266.	1.9	2
85	The Clinical Spectrum and Outcome of Uveomeningitis: A Comprehensive Analysis of 110 Cases. Ocular Immunology and Inflammation, 2022, 30, 1489-1494.	1.8	2
86	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. Autoimmunity Reviews, 2021, 20, 102874.	5.8	2
87	Abdominal adipose tissue predicts major cardiovascular events in systemic necrotising vasculitides. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 130-136.	0.8	2
88	Lymphoplasmacytic lymphoma associated with polyradiculoneuritis andÂcryoglobulinemia mimicking polyarteritis nodosa. Presse Medicale, 2007, 36, 623-626.	1.9	1
89	Characteristics of patients with systemic sclerosis suffering from a lower limb amputation: Results of a French collaborative study. Journal of Scleroderma and Related Disorders, 2020, 5, 224-230.	1.7	1
90	Dr. Pène, <i>et al</i> reply. Journal of Rheumatology, 2016, 43, 677-677.	2.0	0

#	Article	IF	CITATIONS
91	Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report. Journal of Medical Case Reports, 2017, 11, 222.	0.8	0
92	FRIO508â€Analysis of risk factors of adverse obstetrical outcome in patients with takayasu arteritis. , 2018, , .		0
93	Reply to the comment of Fayet et al. Obstacles and motivations to influenza and pneumococcal vaccination in patients with rheumatoid arthritis. A qualitative study. Joint Bone Spine, 2019, 86, 119.	1.6	0
94	Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Joint Bone Spine, 2019, 86, 273-274.	1.6	0
95	THU0312â€ADVENTITIAL FIBROBLAST, AN IMPORTANT PLAYER IN GIANT CELL ARTERITIS. , 2019, , .		0
96	AB0199â€ASSESSING DISABILITY AND QUALITY OF LIFE IN ALGERIAN SYSTEMIC SCLEROSIS PATIENTS: CONSTRUCT VALIDITIES OF THE ARAB HAND FUNCTION INDEX AND HEALTH ASSESSMENT QUESTIONNAIRE (HAQ)., 2019,,.		0
97	O29â€Determination of homogenous subgroups of antiphospholipid syndrome: cluster analysis based on 509 cases. , 2020, , .		0
98	Mental Health Care Use and Associated Factors in Systemic Sclerosis: A Scleroderma <scp>Patient entered</scp> Intervention Network Cohort Study. ACR Open Rheumatology, 0, , .	2.1	0